The PI3K inhibitor alpelisib has been approved by the US Food and Drug Administration and is in the clinical setting in Sweden offered to patients with advanced breast cancer harboring a PIK3CA mutation1. This evidence concerns the gene PIK3CA and breast carcinoma.